What could change its growth trajectory, and what would confirm it?
Sound Vaccine's plan to move ER134, a TSC-based hearing-improvement software designated Innovative Medical Device No. 75 by the Ministry of Food and Drug Safety, toward multinational confirmatory clinical trials represents the clearest stated growth catalyst, though the reported milestone remains a plan, not a completed trial outcome.
Sound Vaccine and Hana Bank are discussing a B2B settlement system that links the company's 32 distributors across the nation with hospitals and clinics. The two companies plan to integrate the hearing assessment tool for ER134 within Hana One Q for remote check-ups and hospital-linked B2C service.
What is the investment case, and what must be true for it to hold?
Sound Vaccine has a credible but still conditional case for advancing TSC-based hearing care: in the randomized trial, 78% of the TSC group and 44% of the control group showed auditory-threshold amelioration with a statistically significant between-group difference, while broader validation and the planned ER134 trials remain necessary for the commercial path.
The planned ER134 trials are multinational confirmatory trials of the TSC-based hearing-improvement software designated Innovative Medical Device No. 75 by the Ministry of Food and Drug Safety. Sound Vaccine and Hana Bank are discussing a B2B integrated settlement system linking the firm's 32 distributors nationwide to hospitals and clinics, and are planning a non-face-to-face check-up and hospital-linked B2C service using ER134 in Hana One Q. Mechanistic and molecular studies remain necessary to fully explain TSC's pathophysiology and mechanism of action.
How does its pricing position it against rivals?
Sound Vaccine's published monthly rates sit substantially above AudioCardio's monthly subscription rates, although the packages and billing periods differ: Monthly is $300 per month, versus AudioCardio's Basic Monthly at $9.99 per month and Pro+ Monthly at $12.99 per month.
The company's Annually membership, labeled 2 Months Free, is priced at $200 per month.
Which risks could break the thesis, and what would warn of them?
ER134's route to prospective clinical validation hinges on Sound Vaccine completing the planned multinational confirmatory clinical trials for that TSC-based hearing-improvement software, which the Ministry of Food and Drug Safety has designated Innovative Medical Device No. 75.
A randomized controlled prospective clinical study found significant improvement in a narrow-band frequency threshold, yet additional physiologic, mechanistic, and molecular research is required to fully explain how TSC works.
What does the product do for its buyer, and how is it delivered?
Sound Vaccine provides a self-administered hearing-care service. The offering is a web-based platform whose stated users are musicians and audio engineers.
Its approach uses a spiral template that produces 31 sweep tones, with seven layers of TSC level in 10 dB steps, each calibrated against the 0 dBHL reference values of ISO 226:2003 as a function of frequency.

Sound Vaccine provides web-based hearing care using Threshold Sound Conditioning for music and audio professionals.